Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients

Nicholas FS Watson*1,2, Zahra Madjd1, Duncan Scrimegour1, Ian Spendlove1, Ian O Ellis3, John H Scholefield2 and Lindy G Durrant1

Address: 1Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, NG5 1PB, UK, 2Section of Gastrointestinal Surgery, University of Nottingham, Queens’ Medical Centre, Nottingham, NG7 2UH, UK and 3Department of Pathology, City Hospital, Nottingham, NG5 1PB, UK

Email: Nicholas FS Watson* - nicholas.watson@nottingham.ac.uk; Zahra Madjd - mzxzm@nottingham.ac.uk; Duncan Scrimegour - mrxsds@gwmail.nottingham.ac.uk; Ian Spendlove - mrxzis@gwmail.nottingham.ac.uk; Ian O Ellis - mrxzie@gwmail.nottingham.ac.uk; John H Scholefield - john.scholefield@nottingham.ac.uk; Lindy G Durrant - lindy.durrant@nottingham.ac.uk

* Corresponding author

Abstract

Background: Advances in our understanding of the molecular biology of colorectal cancer have fuelled the search for novel molecular prognostic markers to complement existing staging systems. Markers assessed in combination may perform better than those considered individually. Using high-throughput tissue microarray technology, we describe the prognostic value of combined p53 / Bcl-2 status in colorectal cancer.

Patients and methods: Tumour samples from 462 patients who underwent elective surgery to resect a primary colorectal cancer between 1994 and 2000 (mean follow-up of 75 months) were assembled in tissue microarray format. Clinico-pathological data including tumour grade, stage, vascular invasion status along with disease specific survival data has been collected prospectively. Immunohistochemical analysis of p53 and Bcl-2 expression was performed using antibodies DO-7 (p53) and 124 (Bcl-2), and results correlated with known clinico-pathological variables and outcomes.

Results: Abnormal nuclear p53 accumulation and Bcl-2 overexpression were detected in 221/445 (49.6%) and 199/437 (45.5%) tumours respectively, with a significant inverse correlation between the two markers (p = 0.023). On univariate analysis no correlations were found between either marker and standard clinico-pathological variables, however nuclear p53 expression was associated with a significantly reduced survival (p = 0.024). Combined analysis of the two markers indicated that 112/432 (24.2%) cases displayed a p53(-)/Bcl-2(+) phenotype, this occurring more frequently in earlier stage tumours. Kaplan-Meier analysis revealed a significant survival advantage in these p53(-)/Bcl-2(+) tumours compared with the remaining cases (p = 0.0032). On multivariate analysis using the Cox proportional hazards model, neither p53 expression nor Bcl-2 expression alone were of independent prognostic significance, however the combined p53(-)/Bcl-2(+) phenotype was significantly associated with a good prognosis in this series (HR 0.659, 95%CI 0.452–0.959, p = 0.029).

Conclusion: Patient stratification by combined p53 / Bcl-2 phenotype provides stage-independent prognostic information in colorectal cancer. Specifically, that up to a quarter of patients display a good prognosis p53(-)/Bcl-2(+) phenotype. This may indicate a more clinically indolent phenotype and a subset of patients for whom less aggressive adjuvant treatment appropriate.
Background
Colorectal cancer kills approximately 500,000 people worldwide each year [1], and treatments which produce only modest improvements in survival may have an enormous health impact. Current practice is to base therapeutic decisions and prognostic advice on clinicopathological data, however within conventional staging groups many genetic and molecular tumour subtypes exist. This heterogeneity of tumour genotypes accounts for much of the observed variation in recurrence rates and clinical responses to available therapies.

Advances in our understanding of the molecular biology of colorectal cancer have fuelled the search for novel molecular prognostic markers with which to complement existing staging systems. Applied to clinical practice, these putative markers could be used to identify groups of patients with differing relative risks of recurrence and improve patient stratification for adjuvant treatment.

Immunohistochemical studies in colorectal cancer have tended to investigate expression of individual proteins in relation to prognosis, and relatively few studies have focused on the analysis of multiple markers in combination. However, one such combination which may be of value in colorectal cancer is the combined p53/Bcl-2 phenotype, as suggested by Manne et al, who described the p53/Bcl-2 phenotype of 134 patients with Dukes stage A-D tumours, finding that this combination gave independent prognostic information which was superior to that of either marker on its own [2]. The same group have subsequently shown in a larger cohort of 234 patients with tumours of the distal colorectum that combined p53/Bcl-2 analysis may provide stronger prognostic information than nodal status [3]. Other researchers have reported similar findings in differing groups of colorectal cancer patients [4,5], with the p53(-)/Bcl-2(+) subset appearing to define a group of patients who appear to have a prolonged survival, although this has not always retained independence on multivariate analysis [6,7]. Alternatively, it has been suggested that opposing p53(+)/Bcl-2(-) phenotype defines a particularly poor prognosis subset [8], or that Bcl-2 positivity in combination with either p53, p21 or mdm-2 confers a good prognosis [9].

Since its first description in 1998, tissue microarray (TMA) analysis [10] has been employed for the immunohistochemical analysis of target protein expression in a wide range of primary tumour types. Initial fears that the reduced amount of individual tumour tissue analysed using this technique might not be representative of the tumour as a whole appear largely unfounded [11], and the strengths of this approach lie in its ability to provide a rapid turnover of results from very large patient cohorts, whilst reducing variability in experimental conditions and reducing costs [12]. Two previous studies have utilised tissue microarray technology to investigate the combination of p53/Bcl-2 in rectal cancer. In the first, Hoos et al, studied 100 patients with lymph-node negative rectal cancer, and found an increased number of deaths in the patients with p53(+)/Bcl-2(-) tumours (7/33, 21.2%) compared with the p53(-)/Bcl-2(+) group (2/13, 15.4%) [13], and a recent study of 269 patients with Dukes stage A-D rectal cancer reported a lower rate of metastatic disease in p53(-)/Bcl-2(+) tumours, with p53(+)/Bcl-2(-) tumours showing a worse outcome [14].

The aim of the present study was to investigate the prognostic significance of the combined p53/Bcl-2 phenotype in a large scale, representative sample of colorectal cancers using tissue microarrays, in order to determine the potential utility of this combination of molecular markers in guiding treatment of patients in the UK.

Patients and methods
Patients and specimens
The study population comprised 462 patients undergoing elective surgery for a single, non-metachronous histologically proven primary colorectal cancer at University Hospital Nottingham between 1st January 1994 and 31st December 2000. Data regarding tumour site, stage, histological type and tumour grade have been recorded prospectively for these patients. Only patients with lymph node positive disease were routinely treated with adjuvant chemotherapy, comprising 5-fluorouracil and folinic acid. The original histopathological slide sets and pathological reports for all cases were obtained from the hospital archives, and reviewed to confirm the diagnosis and the accuracy of existing data. However, in a minority of cases only very limited slide sets were available and the full clinicopathological dataset was incomplete. In addition, we did not attempt to ascertain the vascular invasion status of tumours where this information had not been previously recorded.

Follow-up data regarding the date and cause of death for this cohort of patients has been provided prospectively by the UK Office for National Statistics. Follow-up was calculated from the date of resection of the primary tumour, and all surviving cases were censored for survival analysis at 31st December 2003. Disease specific survival was used as the primary end-point. The Local Research Ethics Committee granted approval for the study.

Preparation of the tissue microarray
Tissue microarrays were constructed as described previously [10]. 5 μm haematoxylin and eosin (H&E) stained slides were used to identify and mark out representative areas of viable tumour tissue. 0.6 mm needle core-biopsies from the relevant areas of corresponding paraffin-
embedded blocks were then placed at defined coordinates in the recipient paraffin array blocks using a manual arrayer (Beecher Instruments, Sun Prairie, WI). Array blocks were constructed at a density of 80–150 cores per array. Analysis of each marker was performed on a single core from each tumour. This typically shows over 90% concordance with conventional whole section analysis of tumour markers and has been validated previously [11].

**Immunohistochemical methods**

Immunohistochemistry was performed using a standard avidin-biotin peroxidase method with p53 mAb clone DO-7 (1:20 dilution, Dako Ltd, Ely, UK) and Bcl-2 mAb clone 124 (1:50, Dako Ltd, Ely, UK). Briefly, 5 µm array sections were deparaffinised with xylene, rehydrated through graded alcohol and immersed in methanol containing 0.3% hydrogen peroxide for 10 minutes to block endogenous peroxidase activity. Heat induced epitope retrieval consisting of 20 minutes microwave treatment in pH 6.0 citrate buffer was necessary with the DO-7 mAb. Endogenous avidin/biotin binding was blocked using an avidin/biotin blocking kit (Vector Labs, USA) and sections were treated with 100 µl of normal swine serum (NSS) for 10 min to block non-specific binding of the primary antibody.

Test sections were incubated with 100 µl of primary antibody for 1 hr at room temperature. Positive control tissue comprised whole sections of human tonsil. Primary antibody was omitted from negative control sections, which were incubated in NSS. After washing with TBS sections were incubated with 100 µl of biotinylated goat antimouse/rabbit immunoglobulin (Dako Ltd, Ely, UK) diluted 1:100 in NSS for 30 min, followed by 100 µl of pre-formed streptavidin-biotin/horseradish peroxidase (HRP) complex (Dako Ltd, Ely, UK) for 60 min at room temperature. Staining was finally visualised using 3, 3'-Diaminobenzidine tetrahydrochloride (DAB, Dako Ltd, Ely, UK).

**Evaluation of staining**

Evaluation of the staining was carried out by two observers (NFSW and ZM) blinded to the clinico-pathological data, with a consensus decision in all cases. For each antigen tumours were classified in two groups with the defined cut-off values of: p53 overexpression if >10% tumour nuclei stained, irrespective of staining intensity, and Bcl-2 overexpression if cytoplasmic staining (any intensity) was identified in >30% of the tumour cells. These values were determined from previous studies using the same reagents in colorectal cancer [13], although it has recently been shown in a meta-analysis that when using the DO-7 antibody, reducing the cut-off value to 1% of the nuclei stained does not alter the outcome of subsequent survival analysis [15]. In order to further investigate the significance of the combined p53 / Bcl-2 phenotypes, the individual staining patterns for these antigens were combined and then analysed as an additional group.

**Statistical methods**

All statistical analyses were performed using the SPSS package (version 11 for Windows, SPSS Inc., Chicago, IL). Associations between categorical variables were examined using cross tabulation and the Pearson chi-square test for categorical variables. Kaplan-Meier curves were derived in order to assess disease-specific survival, and the significance of differences in disease-specific survival between groups was calculated using the log-rank test. Complete outcome data was available for all but one patient in the study. Patients whose deaths related to their colorectal cancer were considered in the disease-specific survival calculations. However, patients who died from postoperative complications (deaths within 1 month of the date of surgery), and patients with carcinoma in-situ (pTis tumors) were excluded from the survival analyses. Deaths resulting from non-colorectal cancer related causes were censored at the time of death. Multivariate analysis using the Cox proportional-hazards model was employed to determine hazard ratios and identify variables with independent prognostic significance in this cohort. In all cases $P$ values <0.05 were considered statistically significant.

**Results**

**Clinico-pathological data**

The arrayed tumours were found to be broadly representative of the spectrum of colorectal cancer encountered in the UK (Table 1). The median age at the time of surgery was 72 years, consistent with a median age at diagnosis of colorectal cancer of 70–74 years in the UK [16]. At the time of censoring for data analysis 49% of patients had died from their disease, 37% were still alive and 14% were deceased from non-colorectal cancer related causes. 38 deaths occurred within one month of surgery. The median length of follow-up available for surviving patients was 75 months (range 36–116). The overall median five-year disease-specific survival for the cohort was 58 months, which is comparable with the approximately 45% five-year survival seen for colorectal cancer in the UK [17].

**Antigen expression**

The observed frequencies of expression for p53 and Bcl-2 are shown in table 2. Although it has previously been stated that the number of cores uninterpretable due to tissue loss or damage in tissue microarray studies may exceed 20–30% of the total, this was not observed in the current study. The highest number of uninterpretable cases (30 cases / 6.5% of total) was seen when the results for p53 and Bcl-2 were combined. Representative examples of positive and negative staining for each antigen are shown in figure 1.
Table 1: Clinico-pathological variables for the patient cohort (n = 462).

| Variable                        | Number  | Percentage |
|---------------------------------|---------|------------|
| Age (years)                     | Median  | 72         |
|                                 | Range   | 57–89      |
| Gender                          | Male    | 266 (58%)  |
|                                 | Female  | 196 (42%)  |
| Status                          | Alive   | 169 (37%)  |
|                                 | Dead (colorectal cancer related) | 228 (49%) |
|                                 | Dead (non-colorectal cancer causes) | 64 (14%)  |
|                                 | Unknown | 1          |
| Histological type               | Adenocarcinoma | 392 (85%) |
|                                 | Mucinous carcinoma | 51 (11%)  |
|                                 | Columnar carcinoma | 4 (1%)    |
|                                 | Signet ring carcinoma | 7 (1%)    |
|                                 | Unknown | 8 (2%)     |
| Histological grade              | Well differentiated | 29 (6%)    |
|                                 | Moderately differentiated | 353 (77%) |
|                                 | Poorly differentiated | 71 (15%)  |
|                                 | Unknown | 9 (2%)     |
| Tumour site                     | Colon   | 238 (52%)  |
|                                 | Rectal  | 181 (39%)  |
|                                 | Unknown | 43 (9%)    |
| TNM stage                       | 0 (Tis) | 3 (1%)     |
|                                 | 1       | 69 (15%)   |
|                                 | 2       | 174 (38%)  |
|                                 | 3       | 155 (33%)  |
|                                 | 4       | 54 (12%)   |
|                                 | Unknown | 7 (2%)     |
| Extramural vascular invasion    | Negative | 224 (48%)  |
|                                 | Positive | 128 (28%)  |
|                                 | Unknown | 110 (24%)  |

Table 2: Frequencies of immunohistochemical expression of p53 and Bcl-2.

| Antigen                      | Number (%) positive (high) | Number (%) negative (low) | Number (%) missing |
|------------------------------|-----------------------------|---------------------------|--------------------|
| p53                          | 221 (47.8)                  | 224 (48.5)                | 17 (3.7)           |
| Bcl-2                        | 199 (43.1)                  | 238 (51.5)                | 25 (5.4)           |
| p53 (-) / Bcl-2 (+) combination | 112 (24.2)               | 320 (69.3)                | 30 (6.5)           |

**p53 expression**

p53 in its wild-type form is undetectable by conventional immunohistochemical methods, due to its short half-life. In contrast, most mutations in the p53 gene lead to expression of a stable protein product which accumulates in the nucleus and is detected by the DO-7 antibody. In this study overexpression of p53 was detected in 221/445 tumours (49.6%). On univariate analysis no associations were found between p53 expression and clinico-pathological variables including tumour grade, stage and the presence of extramural vascular invasion, however a significant relationship was noted between p53 expression and disease specific survival. On Kaplan-Meier analysis (figure 2), patients with p53(-) tumours
demonstrated a significantly longer mean disease specific survival (DSS) of 76 (95% CI 69–83) months, as compared with a mean DSS of 64 (95% CI 57–71) months in patients with p53(+) tumours (p = 0.0240).

**Bcl-2 expression**
Overexpression of Bcl-2 protein was detected in the cytoplasm of 199/437 evaluable tumours (45.5%). In contrast, no nuclear expression of Bcl-2 was observed. Although no strong associations between Bcl-2 expression and clinico-pathological variables were noted, there was a trend on univariate analysis towards increased cytoplasmic accumulation of Bcl-2 in moderate and poorly differentiated tumours compared with well differentiated tumours (p = 0.076). On Kaplan-Meier analysis, no association was found between Bcl-2 expression and survival (p = 0.0865, figure 3).

**p53(-) / Bcl-2(+) phenotype**
Comparing results for both Bcl-2 and p53, a significant reciprocal pattern of expression was seen (table 3, p = 0.023). Combining the results for these two markers, a total of 112/432 tumours (25.9%) displayed the p53(-) / Bcl-2(+) phenotype. A trend was noted toward a higher prevalence of this phenotype in earlier stage tumours, with a prevalence of 33.9%, 26.3%, 24.1% and 14.3% in TNM stage I-IV tumours respectively (p = 0.078). Additional strong correlations were noted between the p53(-) / Bcl-2(+) phenotype and DSS on univariate analysis (p = 0.004), and on Kaplan-Meier analysis, with a mean DSS of

---

Figure 1
A & B show cores from a tumour demonstrating positive staining for p53 (A), and negative staining for Bcl-2 (B). C & D show cores from a p53 negative (C) / Bcl-2 positive (D) tumour. All at x20 original magnification.
84 (95%CI 75–92) months in patients with p53(-) / Bcl-2(+) tumours compared with a mean survival of 65 (95% CI 59–71) months in the remaining patients (figure 4) (p = 0.0032).

Multivariate analysis

HRs for individual markers

A multivariate analysis of factors influencing survival was performed using the Cox proportional hazards model. Analysis included all available cases. Of the conventional clinico-pathological variables analysed, significant independent prognostic value was demonstrated only for TNM stage, and for vascular invasion status. In contrast, neither p53 expression, nor Bcl-2 expression alone were found to be independent markers of prognosis. Considering the combined p53(-) / Bcl-2(+) phenotype, this was found to have independent prognostic value, conferring a significant survival advantage as compared with the other possible combinations of p53 / Bcl-2 expression (table 4).

Discussion

Previous studies have suggested that combined p53 and Bcl-2 immunostaining may provide useful prognostic information in colorectal cancer; however these conclusions have been derived from varying study populations, with heterogeneous methodology and limited sample sizes. To our knowledge no previous study has investigated these findings in such a large, representative cohort of patients from the UK. Using widely validated antibodies and established techniques, our results indicate that patient stratification by combined p53/Bcl-2 phenotype provides tumour stage-independent

Figure 2
Kaplan-Meier plot for disease specific survival, p53 (+) vs p53 (-) tumours (n = 408).

Survival from operation date (months)

Log rank=5.09 ,P=0.0240
prognostic information; specifically, that a subset of up to a quarter of colorectal cancer patients display a good prognosis p53(-)/Bcl-2(+) phenotype.

In line with previous studies, we found no positive correlations between expression of the individual markers and our clinico-pathological data [18]. However, as has been the case previously [19], we noted significant reciprocity of p53 and Bcl-2 expression. Saleh et al, reported an association between Bcl-2 expression and lower p53 levels, a lower mean Ki-67 labelling index and favourable histopathological parameters [20]. Similarly, Popescu et al, demonstrated reciprocal expression of Bcl-2 and p53 mRNA in samples from 19 colorectal cancer metastases

![Kaplan-Meier plot for disease specific survival, Bcl-2 (+) vs Bcl-2 (-) tumours (n = 400).](image-url)

**Table 3: Co-expression of p53 with Bcl-2.**

|                 | Number (%) p53 (+) | Number (%) p53 (-) |
|-----------------|-------------------|-------------------|
| Number (%) Bcl-2 (+) | 129 (29.8)        | 106 (24.5)        |
| Number (%) Bcl-2 (-)  | 87 (20.1)         | 111 (25.6)        |

**Figure 3**

Kaplan-Meier plot for disease specific survival, Bcl-2 (+) vs Bcl-2 (-) tumours (n = 400).
Survival from operation date (months)

Log rank=8.71, p=0.0032

**Figure 4**
Kaplan-Meier plot for disease specific survival comparing p53 (-) / Bcl-2 (+) tumours with alternative phenotypes (n = 396).

| Variable                  | Category       | OR    | 95% CI      | p value |
|---------------------------|----------------|-------|-------------|---------|
| TNM stage                 | I              | 1     |             |         |
|                           | II             | 1.427 | 0.758–2.689 | <0.001  |
|                           | III            | 3.170 | 1.728–5.816 |         |
|                           | IV             | 22.070| 11.309–43.068|        |
|                           | Unknown        | 2.895 | 0.640–13.102|         |
| Vascular invasion status  | Negative       | 1     |             | <0.001  |
|                           | Positive       | 2.156 | 1.525–3.047 |         |
|                           | Unknown        | 1.221 | 0.798–1.869 |         |
| p53/Bcl-2 status          | Non- p53(-) / Bcl-2 (+) | 1 | | |
|                           | P53(-) / Bcl-2 (+) | 0.659 | 0.452–0.959 | 0.029   |
tumours, in agreement with the findings of Gouissa et al, who demonstrated a trend for the p53(-)/Bcl-2(+) phenotype to be associated with lymph node negative tumours in a study of 108 colorectal adenocarcinomas [22].

Two recent papers have systematically reviewed the evidence for a prognostic role of p53 expression in colorectal cancer and illustrate some of the difficulties in interpreting the available literature. In the first, Anwar et al, described 35 studies (24 using immunohistochemical methods) in which p53 was found to be predictive of a worse outcome and 24 papers (16 employing IHC) found no association. In total only 4 of these studies included a comparable number of patients to ours, with 39 studies reporting on <150 cases [23]. In the second review Munro et al, included 168 articles, reporting survival outcomes on a pool of over 18 000 patients. In this large review factors such as sources of heterogeneity between studies, the effect of publication bias and various assumptions concerning the techniques used for assessing p53 abnormalities led them to limit their conclusion to the fact that in patients with a better underlying prognosis, abnormal p53 has an adverse effect on outcome [15].

It appears logical that combined analysis of p53 with Bcl-2 should prove greater than the sum of its parts, as the p53 protein is known to regulate apoptosis via the Bcl-2/BAX pathway. Native p53 inhibits Bcl-2 gene expression by transcriptional activation of the pro-apoptotic gene BAX [24]. Bcl-2 itself is a proto-oncogene, whose expression varies in differing tissues. In the normal gastrointestinal tract Bcl-2 expression has been detected in the basal cells of crypts. Bcl-2 expression has also been described in the majority (up to 85%) of colorectal adenomas, with reduced expression on progression to invasive carcinoma [25,26]. Despite the defined role of Bcl-2 protein in suppression of apoptosis, in colorectal cancer the evidence suggests that Bcl-2 expression is correlated with favourable parameters [27] and a better prognosis [28]. This may be explained by the finding that although Bcl-2 inhibits apoptosis it may also slow cell growth [29]. It has been reported that Bcl-2 contains an anti-proliferative domain, distinct from the domains required for its anti-apoptotic activity [30], and also that Bcl-2 can be converted to a BAX-like death effector by cleavage of a regulatory loop domain by caspases [31]. Whatever the underlying biological mechanism, in this study we have found that the combination of positive cytoplasmic Bcl-2 expression and negative nuclear p53 expression in colorectal cancer defines a population of patients with a good prognosis, indicating a clinically more indolent phenotype and a subset of patients for whom less aggressive adjuvant treatment is indicated.

**Conclusion**

The use of molecular prognostic markers which complement traditional clinico-pathological staging information is not yet widespread in colorectal cancer, mainly due to the lack of high quality prospective studies and concerns regarding reproducibility and generalisation from existing data [32]. In particular, quantitative scoring of immunostaining for practical/diagnostic purposes is a very difficult affair and liable to much subjectivity. This is probably the major reason why so few quantitative immunomarkers have made their way into surgical pathology. These issues need to be addressed if we are to improve on existing prognostic criteria. However, our results suggest that analysis of p53 and Bcl-2 expression in colorectal cancer patients may provide useful prognostic information.

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors' contributions**

LGD, IS, JHS and IOE conceived and designed the study.

JHS was responsible for maintaining the clinical database.

NFSW, ZM and DS were responsible for constructing the tissue arrays, performing the immunohistochemistry and analyzing the results.

All authors were responsible for interpreting the results and drafting the article. All authors read and approved the final manuscript.

**Acknowledgements**

The authors thank Claire Paish and John Ronan for their technical advice. This work was supported in part by a grant from the Special Trustees of Nottingham Hospitals (grant STR/03/M).

**References**

1. Parkin DM: Global cancer statistics in the year 2000. *Lancet Oncol* 2001, 2:533-543.

2. Manne U, Myers RB, Moron C, Pozatek RB, Dillard S, Weiss H, Brown D, Srivastava S, Grizzle WE: Prognostic significance of Bcl-2 expression and nuclear p53 accumulation in colorectal adenocarcinomas. *Int J Cancer (Pred Oncol)* 1997, 74:346-358.

3. Manne U, Weiss HL, Grizzle WE: Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. *Int J Cancer (Pred Oncol)* 2000, 89:423-430.

4. Schwandner O, Schiedeck TH, Bruch HP, Duchtrow M, Windswoevel U, Broll R: p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. *Eur J Cancer* 2000, 36:348-356.

5. Buglioni S, D’Agnano I, Cosimelli M, Vasselli S, D’Angelo C, Tedesco M, Zupi G, Moroless M: Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and Bcl-2. *Int J Cancer (Pred Oncol)* 1999, 84:545-552.
6. Baretton GB, Diebold J, Christoforidis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M, Lohrs U: Apoptosis and immunohistochemical Bcl-2 expression in colorectal adenomas and carcinomas: aspects of carcinogenesis and prognostic significance. Cancer 1996, 77:255-264.

7. Kaklamani L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, Tsitotos P, Mortensen N, Gatter KC, Harris AL: Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. Br J Cancer 1998, 77:1864-1869.

8. Girommanolaki A, Stathopoulos GP, Tsibouanou P, Papadimitriou C, Georgoulis V, Gatter KC, Harris AL, Koukourakis MI: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999, 86:1421-1430.

9. Elbaklawy MA, Maxwell P, Williamon K, Anderson N, Hamilton PW: Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumor stage and patient survival. J Pathol 2001, 194:436-443.

10. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M, Sauter G, Kallioniemi OP: Tissue microarrays for high throughput molecular profiling of tumour specimens. Nature Med 1998, 4:844-847.

11. Camp RL, Alberts EA, Rimm DL: Validation of tissue microarray technology in breast cancer. Lab Invest 2000, 80:1943-1949.

12. Torhorst J, Bucher C, Kononen J, Hass P, Zuber M, Kochli OR, Mross F, Dieterich H, Moeh H, Mihatsch M, Kallioniemi OP, Sauter G: Tissue microarrays for the rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001, 159:2249-2256.

13. Hoos A, Nissan A, Stojadinovic A, Shia J, Hedvat CV, Leung DHY, Pasy PB, Klimstra D, Cordon-Cardo C, Wong WD: Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 2002, 8:3841-3849.

14. Fernebro E, Bendahl PO, Dictor M, Persson A, Ferno M, Nilbert M: Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 2004, 111:921-928.

15. Munro AJ, Lain S, Lane DP: p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005, 92:434-444.

16. Quinn M, Sibb P, Brock A, Kirby L, Jones J: Cancer trends in England and Wales 1950-1999. London: The Stationary Office; 2001.

17. National Institute for Clinical Excellence: Improving outcomes in colorectal cancers: manual update. London: NICE; 2004.

18. Perrone G, Viscenzi B, Santini D, Verzi A, Tonini G, Vettraini A, Rabbici CR: Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett 2004, 208:227-234.

19. Watson AJ, Merritt AJ, Jones LS, Askew JN, Anderson E, Becciolini A, Balzi M, Potten CS, Hickman JA: Evidence of reciprocity of Bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996, 73:889-895.

20. Saleh HA, Jackson H, Banerjee M: Immunohistochemical expression of Bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol 2000, 8:175-182.

21. Popescu RA, Lohri A, de Kant E, Thiede C, Reuter J, Herrmann R, Roczitz C: Bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal carcinoma. Eur J Cancer 1998, 34:1268-1273.

22. Gouissac AC, Ioachim E, Aignantis NJ, Mahera M, Tsianos EV: Bcl-2 expression in colorectal tumours. Correlation with p53, mdm-2, Rb proteins and proliferation indices. Histopathology 2000, 36:567-672.

23. Anwar S, Frayling IM, Scott NA, Carlson GL: Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 2004, 91:1275-1291.

24. Miyashita T, Krajewski S, Krajewski M, Wang HD, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805.

25. Kaklamani L, Savage A, Mortensen N, Tsitotos P, Doussis-Anagnostopoulou I, Biddolph S, Whitehouse R, Harris AL, Gatter KC: Early expression of bcl-2 protein in the adenoma-carcinoma sequence. J Pathol 1996, 179:10-14.

26. Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G, Viale G: Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995, 26:534-540.

27. Sincrco FA, Hart J, Michelassi F, Lee JJ: Prognostic value of Bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995, 1:1103-1110.

28. Ofrner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B, Schmid KW: Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer 1995, 72:981-985.

29. Pietenpol JA, Papadopoulos N, Markowitz S, Wilson JK, Kinzler KW, Vogelstein B: Paradoxical inhibition of solid tumor growth by Bcl-2. Cancer Res 1994, 54:3714-3717.

30. Theodorsakis P, D’Sa-Epper C, Subramanian T, Chinnadurai G: Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1. Oncogene 1996, 12:1707-1713.

31. Cheng EHY, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM: Conversion of Bcl-2 to a BAX-like death effector by caspases. Science 1997, 278:966-1968.

32. Graziano F, Caccuri S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Duke’s B colorectal cancer patients: how much evidence is enough? Ann Oncology 2003, 14:1026-1038.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp